← 返回

NK 细胞来源外泌体为基础的癌症治疗:从生物学作用到临床意义和启示

英文原题:Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications.

查看英文原题

Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications.

PubMed 2024/06/29(内容时间) Mol Cancer Q1 · IF 42.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞是机体重要的免疫细胞,是除T细胞和B细胞之外的第三大类淋巴细胞,在肿瘤治疗中发挥重要功能。NK 细胞来源的外泌体除保留NK 细胞的肿瘤细胞杀伤功能外,还具有安全性高、来源广泛、易于保存和运输等特点。同时,NK 细胞来源的外泌体易于修饰,工程化外泌体可与当前多种肿瘤治疗方法联合使用,不仅能增强治疗效果,还能显著降低副作用。因此,本文综述了NK 细胞来源外泌体的来源、分离和修饰策略,以及NK 细胞来源工程化外泌体与其他抗肿瘤治疗的联合应用,有望加速NK 细胞来源工程化外泌体在肿瘤治疗中的临床转化进程。

展开英文摘要原文

Natural killer (NK) cells are important immune cells in the organism and are the third major type of lymphocytes besides T cells and B cells, which play an important function in cancer therapy.

In addition to retaining the tumor cell killing function of natural killer cells, natural killer cell-derived exosomes cells also have the characteristics of high safety, wide source, easy to preserve and transport. At the same time, natural killer cell-derived exosomes are easy to modify, and the engineered exosomes can be used in combination with a variety of current cancer therapies, which not only enhances the therapeutic efficacy, but also significantly reduces the side effects.

Therefore, this review summarizes the source, isolation and modification strategies of natural killer cell-derived exosomes and the combined application of natural killer cell-derived engineered exosomes with other antitumor therapies, which is expected to accelerate the clinical translation process of natural killer cell-derived engineered exosomes in cancer therapy.

论文信息

作者
Si C、Gao J、Ma X
第一作者单位
National Research Institute for Family Planning, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100000, China.China
通讯作者单位
National Research Institute for Family Planning, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100000, China. maxu@nrifp.org.cn.China
文献类型
综述
期刊
Molecular cancer2024 Jun 29
原文标识
PubMed 38951879 · DOI 10.1186/s12943-024-02045-4